National Toxicology Program

National Toxicology Program
http://ntp.niehs.nih.gov/go/ts-m930062

Testing Status of Dicyclohexylcarbodiimide - M930062

 

CASRN: 538-75-0

Formula: C13-H22-N2

Synonyms/Common Names

  • Bis(cyclohexyl)carbodiimide
  • DCC

Known Uses

Widely used reagent in the chemical and pharmaceutical industries; increasing use in field of bioenergetics; stabilizing agent in elastomers, natural rubber, and many types of polyolefins, polyesters, resins, fibers, cellulose esters, etc.

Chemical Properties

Toxicity Effects (HSDB)

Nomination Background

Short-Term Toxicity

  • 2 weeks (Topical Application)  (C93021)  Completed 
    • Rats: F344/N; Mice: B6C3F1
    • Dose: R&M: 0, 2, 6, 17, 50, OR 150 MG/ML; 5/SEX/SPECIES/GROUP.
  • 20 weeks (Topical Application)  (C93021B)  Completed 
    • GMM-09 (NIH Number: 07-4426)  (Peer Review Approval 08/28/2006A )
      Toxicology Studies of Dicyclohexylcarbodiimide (CASRN 538-75-0) in F344/N Rats, B6C3F1 Mice, and Genetically Modified (FVB Tg.AC Hemizygous) Mice and Carcinogenicity Study of Dicyclohexylcarbodiimide in Genetically Modified [B6.129-Trp53tm1Brd (N5) Haploinsufficient] Mice (Dermal Studies)
    • Mice: Tg.AC (FVB/N) Hemizygous
    • Dose: FEMALE MICE: 0, 0.75, 1.5, 3, 6, 12 MG/KG; 10/GROUP.
  • 27 weeks (Topical Application)  (C93021C)  Completed 
    • GMM-09 (NIH Number: 07-4426)  (Peer Review Approval 08/28/2006A )
      Toxicology Studies of Dicyclohexylcarbodiimide (CASRN 538-75-0) in F344/N Rats, B6C3F1 Mice, and Genetically Modified (FVB Tg.AC Hemizygous) Mice and Carcinogenicity Study of Dicyclohexylcarbodiimide in Genetically Modified [B6.129-Trp53tm1Brd (N5) Haploinsufficient] Mice (Dermal Studies)
    • Mice: P53 +/- (C57BL/6)
    • Dose: 0, 0.75, 1.5, 3, 6, OR 12 MG/KG; 15/GROUP.
  • 13 weeks (Topical Application)  (C93021)  Completed 
    • GMM-09 (NIH Number: 07-4426)  (Peer Review Approval 08/28/2006A )
      Toxicology Studies of Dicyclohexylcarbodiimide (CASRN 538-75-0) in F344/N Rats, B6C3F1 Mice, and Genetically Modified (FVB Tg.AC Hemizygous) Mice and Carcinogenicity Study of Dicyclohexylcarbodiimide in Genetically Modified [B6.129-Trp53tm1Brd (N5) Haploinsufficient] Mice (Dermal Studies)
    • Rats: F344/N; Mice: B6C3F1
    • Dose: R: 0, 0.75, 1.5, 3, 6, OR 12 MG/KG M: 0, 1.5, 3, 6, 12, OR 24 MG/KG; 10/SEX/SPECIES/GROUP; 6 GROUPS.

Special Studies

  • Absorption Disposition Metabolism Elimination (Intravenous; Topical Application)  (S0663)  Completed 
    • Citation: Disposition of Dermally and Intravenously Administered [14C]Dicyclohexylcarbodlimide in Fischer 344 Rats and B6C3F1 Mice January 4, 1999
    • Male Rats: F344/N; Male Mice: B6C3F1; Male Rats: F344/N; Male Mice: B6C3F1

Genetic Toxicology

  • Micronucleus  (A45449)  Completed 
    • Citation: Witt, K.L., Tice, R.R., Shelby, M.D., Chhabra, R.S., and Zeiger, E. Induction of Micronucleated Erythrocytes in Rodents by Diisopropylcarbodiimide and Dicyclohexylcarbodiimide: Dependence on Exposure Protocol. Environ. Molec. Mutag. Vol. 33 (1999) 65-74
    • Rats: Fischer 344
    • Male Negative 
  • Micronucleus  (A63966)  Completed 
    • Citation: Witt, K.L., Tice, R.R., Shelby, M.D., Chhabra, R.S., and Zeiger, E. Induction of Micronucleated Erythrocytes in Rodents by Diisopropylcarbodiimide and Dicyclohexylcarbodiimide: Dependence on Exposure Protocol. Environ. Molec. Mutag. Vol. 33 (1999) 65-74
    • Mice: B6C3F1
    • Male Weakly Positive 
    • Female Weakly Positive 
  • Salmonella  (A46724)  Completed 
    •  Negative 

Organ Systems Toxicity

  • 4 days, 6 days, 8 days Immunotoxicity (Topical Application)  (IMM96015)  Completed 
    • Female Mice: B6C3F1
    • Dose: 0, .003, .006, .03, & .06% IN ACETONE (99.8%) FOR SENSITIZATION, & .1% FOR CHALLENGE IN THE MEST & .006, .03, .06, AND .1% FOR SENSITIZATION IN THE LLNA. 25% DNFB WAS USED AS THE POSITIVE CONTROL FOR SENSITIZATION, & .5% FOR CHALLENGE.
NTP is located at the National Institute of Environmental Health Sciences, part of the National Institutes of Health.